J. Rocha

发表

Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease

W. Poewe, O. Rascol, A. Lees, 2018, Neurology.

Etamicastat, a novel dopamine β-hydroxylase inhibitor: tolerability, pharmacokinetics, and pharmacodynamics in patients with hypertension.

P. Soares-da-Silva, J. Rocha, Raquel Costa, 2013, Clinical therapeutics.

Cardiac safety profile of etamicastat, a novel peripheral selective dopamine-β-hydroxylase inhibitor in non-human primates, human young and elderly healthy volunteers and hypertensive patients

A. Falcão, P. Soares-da-Silva, P. Lacroix, 2015 .

Safety, Tolerability, and Pharmacokinetics of Etamicastat, a Novel Dopamine-β-Hydroxylase Inhibitor, in a Rising Multiple-Dose Study in Young Healthy Subjects

A. Falcão, P. Soares-da-Silva, J. Rocha, 2010, Drugs in R&D.

Opicapone, a Novel Catechol‐O‐Methyltranferase Inhibitor (COMT) to Manage the Symptoms of Parkinson's Disease

L. Kiss, M. Bonifácio, J. Rocha, 2018 .

Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers.

A. Falcão, P. Soares-da-Silva, J. Rocha, 2009, Molecular nutrition & food research.

Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial

Werner Poewe, Andrew Lees, Olivier Rascol, 2016, The Lancet Neurology.

Opicapone as an Add-on to Levodopa in Patients with Parkinson’s Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON Trial

W. Poewe, O. Rascol, J. Ferreira, 2022, Neurological Therapeutics.

Long‐term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open‐label extensions

W. Poewe, O. Rascol, A. Lees, 2019, European journal of neurology.

Safety Profile of Opicapone in the Management of Parkinson's Disease.

W. Poewe, O. Rascol, A. Lees, 2019, Journal of Parkinson's disease.

Effect of opicapone multiple‐dose regimens on levodopa pharmacokinetics

A. Falcão, P. Soares-da-Silva, N. Fauchoux, 2017, British journal of clinical pharmacology.

Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations

A. Falcão, P. Soares-da-Silva, J. Rocha, 2014, European Journal of Clinical Pharmacology.

Opicapone pharmacokinetics and pharmacodynamics comparison between healthy Japanese and matched white subjects

A. Falcão, P. Soares-da-Silva, J. Rocha, 2016, Clinical pharmacology in drug development.

Concerns Regarding Opicapone as Adjunct to Levodopa Therapy-Reply.

A. Lees, P. Soares-da-Silva, J. Rocha, 2017, JAMA neurology.

Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects.

A. Falcão, P. Soares-da-Silva, M. Bonifácio, 2013, British journal of clinical pharmacology.

Pharmacokinetics, Pharmacodynamics and Tolerability of Opicapone, a Novel Catechol-O-Methyltransferase Inhibitor, in Healthy Subjects

A. Falcão, P. Soares-da-Silva, M. Bonifácio, 2013, Clinical Pharmacokinetics.

Pharmacokinetic-Pharmacodynamic Interaction between Nebicapone, a Novel Catechol-O-Methyltransferase Inhibitor, and Controlled-Release Levodopa/Carbidopa 200 mg/50 mg

A. Falcão, P. Soares-da-Silva, J. Rocha, 2008, Drugs in R&D.

Evaluation of opicapone on cardiac repolarization in a thorough QT/QTc study

A. Patat, A. Falcão, P. Soares-da-Silva, 2015, Clinical pharmacology in drug development.

Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study

O. Witte, D. Gruber, A. Kupsch, 2020, Translational Neurodegeneration.

The safety/tolerability of opicapone when used early in Parkinson's disease patients with levodopa-induced motor fluctuations: A post-hoc analysis of BIPARK-I and II

E. Tolosa, W. Poewe, O. Rascol, 2022, Frontiers in Neurology.

Opicapone as an Add-on to Levodopa in Patients with Parkinson’s Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON Trial

W. Poewe, O. Rascol, J. Ferreira, 2022, Neurology and Therapy.

Efficacy and safety of opicapone in patients with Parkinson’s disease and motor fluctuations: 1-year follow-up (bipark I)

A. Lees, J. Ferreira, P. Soares-da-Silva, 2015, Journal of Neurological Sciences.

Safety, Tolerability, and Pharmacokinetics of FAAH Inhibitor BIA 10‐2474: A Double‐Blind, Randomized, Placebo‐Controlled Study in Healthy Volunteers

P. Pressman, A. Wallace Hayes, A. Falcão, 2021, Clinical pharmacology and therapeutics.

Single‐Dose Tolerability, Pharmacokinetics, and Pharmacodynamics of Etamicastat (BIA 5–453), a New Dopamine β‐Hydroxylase Inhibitor, in Healthy Subjects

A. Falcão, P. Soares-da-Silva, M. Bonifácio, 2012, Journal of clinical pharmacology.

Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations

A. Falcão, P. Soares-da-Silva, J. Rocha, 2014, European Journal of Clinical Pharmacology.

Effect of moderate liver impairment on the pharmacokinetics of opicapone

A. Falcão, P. Soares-da-Silva, J. Rocha, 2014, European Journal of Clinical Pharmacology.

Effect of eslicarbazepine acetate and oxcarbazepine on cognition and psychomotor function in healthy volunteers

E. Sellers, D. Milovan, P. Soares-da-Silva, 2010, Epilepsy & Behavior.

Eslicarbazepine acetate exposure in pregnant women with epilepsy

P. Soares-da-Silva, J. Rocha, H. Gama, 2018, Seizure.

The Parkinson’s Real-World Impact Assessment (PRISM) Study: A European Survey of the Burden of Parkinson’s Disease in Patients and their Carers

E. Tolosa, O. Rascol, G. Ebersbach, 2021, Journal of Parkinson's disease.

Effect of food on the pharmacokinetic profile of trans-resveratrol.

A. Falcão, P. Soares-da-Silva, J. Rocha, 2008, International journal of clinical pharmacology and therapeutics.

Pharmacokinetics of Trans‐resveratrol Following Repeated Administration in Healthy Elderly and Young Subjects

A. Falcão, P. Soares-da-Silva, J. Rocha, 2009, Journal of clinical pharmacology.

Effect of opicapone on levodopa pharmacokinetics, catechol‐O‐methyltransferase activity and motor fluctuations in patients with Parkinson's disease

A. Falcão, P. Soares-da-Silva, J. Rocha, 2015, European journal of neurology.

Response: Comparing the dosages of lacosamide, eslicarbazepine acetate, and controlled‐release carbamazepine in noninferiority epilepsy monotherapy trials: How much “fair” is “fair”

E. Trinka, P. Soares-da-Silva, J. Rocha, 2018, Epilepsia.

Redefining the strategy for the use of COMT inhibitors in Parkinson’s disease: the role of opicapone

O. Rascol, J. Ferreira, P. Jenner, 2021, Expert review of neurotherapeutics.

Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial

W. Poewe, O. Rascol, A. Lees, 2017, JAMA neurology.

Steady‐state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers

A. Falcão, P. Soares-da-Silva, J. Rocha, 2013, Epilepsia.

Effect of Food on the Pharmacokinetic Profile of Etamicastat (BIA 5-453)

A. Falcão, J. Rocha, L. Almeida, 2011, Drugs in R&D.

Pharmacokinetics and tolerability of etamicastat following single and repeated administration in elderly versus young healthy male subjects: an open-label, single-center, parallel-group study.

A. Falcão, P. Soares-da-Silva, J. Rocha, 2011, Clinical therapeutics.

Adjunctive eslicarbazepine acetate: A pooled analysis of three phase III trials

C. Elger, G. Krauss, E. Trinka, 2017, Epilepsy & Behavior.

Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study

D. Gruber, A. Kupsch, H. Reichmann, 2020, Translational Neurodegeneration.

The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II

E. Tolosa, W. Poewe, O. Rascol, 2021, Frontiers in Neurology.

Opicapone versus placebo in the treatment of Parkinson’s disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial

O. Rascol, K. Chaudhuri, A. Storch, 2022, BMC Neurology.

Effect of 3 Single‐Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol‐O‐Methyltransferase Activity and Motor Response in Patients With Parkinson Disease

J. Ferreira, A. Falcão, P. Soares-da-Silva, 2016, Clinical pharmacology in drug development.

A Double‐Blind, Randomized, Placebo and Active‐Controlled Study of Nebicapone for the Treatment of Motor Fluctuations in Parkinson's Disease

W. Poewe, O. Rascol, C. Sampaio, 2010, CNS neuroscience & therapeutics.

Efficacy and safety of eslicarbazepine acetate as adjunctive therapy for refractory focal-onset seizures in children: A double-blind, randomized, placebo-controlled, parallel-group, multicenter, phase-III clinical trial

F. Kirkham, S. Auvin, A. Falcão, 2020, Epilepsy & Behavior.

Efficacy and safety of eslicarbazepine acetate versus controlled‐release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double‐blind, randomized, parallel‐group, multicenter study

C. Elger, E. Ben-Menachem, E. Trinka, 2018, Epilepsia.

Pooled efficacy and safety of eslicarbazepine acetate as add‐on treatment in patients with focal‐onset seizures: Data from four double‐blind placebo‐controlled pivotal phase III clinical studies

C. Elger, E. Trinka, A. Gil-Nagel, 2017, CNS neuroscience & therapeutics.

Pharmacokinetic interaction study between eslicarbazepine acetate and lamotrigine in healthy subjects

A. Falcão, P. Soares-da-Silva, J. Rocha, 2010, Acta neurologica Scandinavica.

Dosage Form Proportionality and Food Effect of the Final Tablet Formulation of Eslicarbazepine Acetate

C. Fontes-Ribeiro, A. Falcão, P. Soares-da-Silva, 2008, Drugs in R&D.

Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease

W. Poewe, O. Rascol, A. Antonini, 2022, Movement disorders : official journal of the Movement Disorder Society.

Safety, Tolerability and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy in Patients Aged ≥ 65 Years with Focal Seizures

B. Steinhoff, P. Soares-da-Silva, J. Rocha, 2018, Drugs & Aging.

Pharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjects

A. Falcão, P. Soares-da-Silva, J. Rocha, 2010, Current medical research and opinion.

Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study

O. Witte, D. Gruber, A. Kupsch, 2020, Translational Neurodegeneration.

Ef ﬁ cacy and safety of eslicarbazepine acetate as adjunctive therapy for refractory focal-onset seizures in children: A double-blind, randomized, placebo-controlled, parallel-group, multicenter, phase-III clinical trial

F. Kirkham, S. Auvin, A. Falcão, 2020 .

Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.

A. Falcão, P. Soares-da-Silva, J. Rocha, 2009, Clinical Therapeutics.

Effect of eslicarbazepine acetate on the pharmacokinetics of metformin in healthy subjects.

C. Fontes-Ribeiro, A. Falcão, P. Soares-da-Silva, 2009, International journal of clinical pharmacology and therapeutics.

Effect of moderate liver impairment on the pharmacokinetics of opicapone

A. Falcão, P. Soares-da-Silva, J. Rocha, 2013, European Journal of Clinical Pharmacology.

Opicapone pharmacokinetics and pharmacodynamics comparison between healthy Japanese and matched white subjects

A. Falcão, P. Soares-da-Silva, J. Rocha, 2016, Clinical pharmacology in drug development.